vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and Enpro Inc. (NPO). Click either name above to swap in a different company.
Enpro Inc. is the larger business by last-quarter revenue ($295.4M vs $199.9M, roughly 1.5× Apellis Pharmaceuticals, Inc.). Enpro Inc. runs the higher net margin — -10.8% vs -29.5%, a 18.7% gap on every dollar of revenue. On growth, Enpro Inc. posted the faster year-over-year revenue change (14.3% vs -5.9%). Over the past eight quarters, Apellis Pharmaceuticals, Inc.'s revenue compounded faster (7.7% CAGR vs 7.1%).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
Enpro is a US-based industrial technology company that designs and manufactures products and materials for technology-intensive sectors. The company serves industries such as semiconductors, aerospace, power generation, heavy-duty trucking, agricultural machinery, chemical processing, pulp and paper, and life sciences from 61 primary manufacturing facilities located in 12 countries, worldwide. It is organized under three segments: Sealing Technologies, Advanced Surface Technologies, and Engin...
APLS vs NPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $295.4M |
| Net Profit | $-59.0M | $-32.0M |
| Gross Margin | — | 42.1% |
| Operating Margin | -25.6% | 11.2% |
| Net Margin | -29.5% | -10.8% |
| Revenue YoY | -5.9% | 14.3% |
| Net Profit YoY | -62.2% | -330.2% |
| EPS (diluted) | $-0.40 | $-1.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $199.9M | $295.4M | ||
| Q3 25 | $458.6M | $286.6M | ||
| Q2 25 | $178.5M | $288.1M | ||
| Q1 25 | $166.8M | $273.2M | ||
| Q4 24 | $212.5M | $258.4M | ||
| Q3 24 | $196.8M | $260.9M | ||
| Q2 24 | $199.7M | $271.9M | ||
| Q1 24 | $172.3M | $257.5M |
| Q4 25 | $-59.0M | $-32.0M | ||
| Q3 25 | $215.7M | $21.6M | ||
| Q2 25 | $-42.2M | $26.4M | ||
| Q1 25 | $-92.2M | $24.5M | ||
| Q4 24 | $-36.4M | $13.9M | ||
| Q3 24 | $-57.4M | $19.8M | ||
| Q2 24 | $-37.7M | $26.7M | ||
| Q1 24 | $-66.4M | $12.5M |
| Q4 25 | — | 42.1% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | — | 43.3% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 42.3% | ||
| Q3 24 | — | 42.3% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | -25.6% | 11.2% | ||
| Q3 25 | 48.7% | 14.3% | ||
| Q2 25 | -18.6% | 15.9% | ||
| Q1 25 | -50.0% | 15.3% | ||
| Q4 24 | -12.3% | 12.5% | ||
| Q3 24 | -24.0% | 13.1% | ||
| Q2 24 | -14.7% | 17.7% | ||
| Q1 24 | -36.0% | 10.9% |
| Q4 25 | -29.5% | -10.8% | ||
| Q3 25 | 47.0% | 7.5% | ||
| Q2 25 | -23.6% | 9.2% | ||
| Q1 25 | -55.3% | 9.0% | ||
| Q4 24 | -17.1% | 5.4% | ||
| Q3 24 | -29.2% | 7.6% | ||
| Q2 24 | -18.9% | 9.8% | ||
| Q1 24 | -38.5% | 4.9% |
| Q4 25 | $-0.40 | $-1.50 | ||
| Q3 25 | $1.67 | $1.01 | ||
| Q2 25 | $-0.33 | $1.25 | ||
| Q1 25 | $-0.74 | $1.15 | ||
| Q4 24 | $-0.30 | $0.65 | ||
| Q3 24 | $-0.46 | $0.94 | ||
| Q2 24 | $-0.30 | $1.27 | ||
| Q1 24 | $-0.54 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $114.7M |
| Total DebtLower is stronger | — | $655.3M |
| Stockholders' EquityBook value | $370.1M | $1.5B |
| Total Assets | $1.1B | $2.7B |
| Debt / EquityLower = less leverage | — | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $466.2M | $114.7M | ||
| Q3 25 | $479.2M | $132.9M | ||
| Q2 25 | $370.0M | $107.1M | ||
| Q1 25 | $358.4M | $240.3M | ||
| Q4 24 | $411.3M | $236.3M | ||
| Q3 24 | $396.9M | $206.9M | ||
| Q2 24 | $360.1M | $175.9M | ||
| Q1 24 | $325.9M | $163.9M |
| Q4 25 | — | $655.3M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $640.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | $644.9M |
| Q4 25 | $370.1M | $1.5B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.5B | ||
| Q1 25 | $164.2M | $1.5B | ||
| Q4 24 | $228.5M | $1.4B | ||
| Q3 24 | $237.1M | $1.5B | ||
| Q2 24 | $264.3M | $1.4B | ||
| Q1 24 | $266.7M | $1.4B |
| Q4 25 | $1.1B | $2.7B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $821.4M | $2.4B | ||
| Q1 25 | $807.3M | $2.5B | ||
| Q4 24 | $885.1M | $2.5B | ||
| Q3 24 | $901.9M | $2.5B | ||
| Q2 24 | $904.5M | $2.5B | ||
| Q1 24 | $831.9M | $2.5B |
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | — |
| Free Cash FlowOCF − Capex | $-14.3M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 0.1% | 4.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $65.3M | ||
| Q2 25 | $4.4M | $52.2M | ||
| Q1 25 | $-53.4M | $21.0M | ||
| Q4 24 | $19.4M | $59.4M | ||
| Q3 24 | $34.1M | $54.0M | ||
| Q2 24 | $-8.3M | $43.2M | ||
| Q1 24 | $-133.0M | $6.3M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $53.4M | ||
| Q2 25 | $4.4M | $42.3M | ||
| Q1 25 | $-53.4M | $13.0M | ||
| Q4 24 | $19.3M | $49.1M | ||
| Q3 24 | — | $48.3M | ||
| Q2 24 | $-8.4M | $38.3M | ||
| Q1 24 | $-133.3M | $-1.9M |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 18.6% | ||
| Q2 25 | 2.5% | 14.7% | ||
| Q1 25 | -32.0% | 4.8% | ||
| Q4 24 | 9.1% | 19.0% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | -4.2% | 14.1% | ||
| Q1 24 | -77.3% | -0.7% |
| Q4 25 | 0.1% | 4.1% | ||
| Q3 25 | 0.0% | 4.2% | ||
| Q2 25 | 0.0% | 3.4% | ||
| Q1 25 | 0.0% | 2.9% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | 0.0% | 1.8% | ||
| Q1 24 | 0.2% | 3.2% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 3.02× | ||
| Q2 25 | — | 1.98× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 4.27× | ||
| Q3 24 | — | 2.73× | ||
| Q2 24 | — | 1.62× | ||
| Q1 24 | — | 0.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NPO
| Sealing Technologies Segment | $187.0M | 63% |
| General Industrial | $71.3M | 24% |
| Power Generation | $19.9M | 7% |
| Oiland Gas Market | $15.0M | 5% |
| Semiconductors | $2.2M | 1% |
